Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced the granting of non-qualified stock options to a newly hired employee. The Compensation Committee approved options to purchase 34,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. These options, granted on August 29, 2024, have an exercise price of $39.17 per share, equal to the closing price of IDEAYA's stock on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will feature a fireside chat with Yujiro S. Hata, CEO of IDEAYA, hosted by Judah Frommer, Executive Director and Senior Equity Research Analyst at Morgan Stanley.

The conference is scheduled for Wednesday, September 4th, 2024 at 5:35 PM ET. Investors and interested parties can access a live audio webcast of the event through the 'Investors/Events' section of IDEAYA's website or via the conference host. The webcast replay will be available for 30 days following the live event, providing an opportunity for those unable to attend to catch up on the discussion.

IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to a newly hired employee. The Compensation Committee approved options to purchase 150,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. These options, granted on August 19, 2024, have an exercise price of $39.06 per share, matching the closing price of IDEAYA's stock on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (NASDAQ: IDYA) reported Q2 2024 financial results and provided a business update. Key highlights include:

• Darovasertib achieved triple-digit enrollment in Phase 2/3 trial for 1L HLA-A2*02:01(-) MUM and over 50 patients enrolled in Phase 2 neoadjuvant UM study
• IDE397 demonstrated preliminary proof-of-concept in MTAP urothelial and lung cancer
• Targeting Werner IND and MTAP/KAT6 pathway DCs in H2'24
• $952.7 million cash position as of June 30, 2024, supplemented by $283.8 million from July 2024 public offering
• Anticipates funding operations into at least 2028

The company made significant progress across its precision medicine oncology pipeline and is on track to deliver its fifth potential first-in-class program to the clinic this year.

Biocytogen and IDEAYA Biosciences have entered into an option and license agreement for a potential first-in-class B7H3/PTK7 bispecific antibody drug conjugate (BsADC) program. The agreement grants IDEAYA an option for an exclusive worldwide license for the program, which targets B7H3/PTK7 co-expression found in multiple solid tumor types. Biocytogen will receive an upfront fee and potential milestone payments totaling $406.5 million, including $100 million in development and regulatory milestones, plus single-digit royalties on net sales.

The BsADC program has the potential to be developed as a monotherapy and in combination with IDEAYA's DNA Damage Repair (DDR) pipeline, including IDE161 (PARG inhibitor). A development candidate nomination is targeted for H2 2024. This collaboration leverages Biocytogen's RenLite® platform and proprietary linker-payload technology to enhance ADC precision and potency.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the upcoming 2024 BTIG Virtual Biotechnology Conference. The event is scheduled for Monday, August 5th, 2024 at 10:00 AM ET.

The conference will feature a fireside chat with Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences, hosted by Justin Zelin, Director of Biotechnology Research Analysis at BTIG. This virtual event provides an opportunity for investors to gain insights into IDEAYA's latest developments in targeted therapeutics for oncology.

A live audio webcast of the conference event will be made available through the conference host, allowing interested parties to tune in remotely.

IDEAYA Biosciences (Nasdaq: IDYA) announced the closing of its public offering, including the full exercise of underwriters' option to purchase additional shares. The offering included 8,355,714 common shares at $35.00 each and pre-funded warrants for 285,715 shares at $34.9999 each, generating approximately $302.4 million in gross proceeds. The offering was managed by J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets. The final prospectus is available on the SEC's website.

IDEAYA Biosciences (Nasdaq: IDYA) has announced the pricing for its underwritten public offering of common stock and pre-funded warrants, totaling approximately $263 million in gross proceeds.

The offering includes 7,228,572 shares of common stock at $35.00 per share and 285,715 pre-funded warrants at $34.9999 per warrant. Each pre-funded warrant has an exercise price of $0.0001 per share.

Additionally, underwriters have a 30-day option to purchase up to an extra 1,127,142 shares at the public offering price. The offering is expected to close around July 11, 2024, subject to customary closing conditions.

J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets are serving as joint book-running managers.

IDEAYA Biosciences (Nasdaq: IDYA) has announced a proposed public offering of up to $200 million in common stock and pre-funded warrants.

The company will also grant underwriters a 30-day option to purchase an additional $30 million in common stock.

The offering is subject to market conditions and other factors, with no assurance of completion or specific terms.

J.P. Morgan, Goldman Sachs, Jefferies, and RBC Capital Markets are acting as joint book-running managers.

This offering will be conducted under an automatically effective shelf registration statement filed with the SEC, and will be made available via a written prospectus and a prospectus supplement.